Preparing the Joint for Regeneration: Why RegeneZone Uses Senolytic Therapy Before Joint Injections *Educational Purposes Only*
RegeneZone™ | The Science of Regenerative Medicine
What if the success of regenerative medicine depends not only on what we inject into a joint, but also on the biological environment we prepare before the injection?
For years, regenerative medicine has focused on the therapeutic products introduced into damaged joints. But a growing body of research suggests that the condition of the patient's existing cells may be equally important.
At RegeneZone, this understanding has helped shape our approach to joint regeneration. We incorporate a senolytic preconditioning protocol using dasatinib and quercetin (D+Q) before selected regenerative joint injections, with the goal of addressing one of the underlying biological contributors to joint degeneration: cellular senescence.
This approach is informed by promising laboratory, animal, and early human research. However, whether D+Q pretreatment improves regenerative injection outcomes in humans remains unproven.
The Problem with Aging Joints: Senescent Cells
As we age, some cells lose their ability to divide and function normally. Rather than being eliminated, they can enter a state known as cellular senescence.
These cells are sometimes called "zombie cells" because they remain alive but may contribute to dysfunction in surrounding tissues.
Senescent cells can release inflammatory molecules, growth factors, and tissue-degrading enzymes collectively known as the senescence-associated secretory phenotype, or SASP.
In osteoarthritic joints, this process can contribute to persistent inflammation, cartilage degradation, and abnormal remodeling of the bone beneath the cartilage.
The problem extends beyond the senescent cells themselves. Their inflammatory signaling can influence neighboring healthy cells, creating an environment that may become increasingly unfavorable for normal tissue maintenance and repair.
This raises an important question: Why introduce regenerative biologics into a joint without first considering the dysfunctional cellular environment already present?
Senolytic Therapy: Addressing the Cells That Contribute to Degeneration
Senolytic therapies are being investigated for their ability to selectively eliminate certain populations of senescent cells by disrupting the survival mechanisms that allow them to resist programmed cell death.
Two compounds receiving considerable scientific attention are dasatinib, a prescription tyrosine kinase inhibitor, and quercetin, a naturally occurring plant flavonoid.
When combined, D+Q has demonstrated senolytic activity in several experimental models.
The objective is not simply to suppress inflammation temporarily, but to investigate whether reducing the burden of dysfunctional cells responsible for producing inflammatory signals can improve tissue biology.
This distinction is particularly important in osteoarthritis, where inflammation, cartilage deterioration, and cellular senescence can reinforce one another.
Can Removing Senescent Cells Restore Cartilage Function?
One of the most compelling studies was published in Aging Cell in 2025 by Maurer and colleagues.
The investigators examined the effects of D+Q on human osteoarthritic chondrocytes and cartilage tissue samples. They found that treatment reduced senescence-associated cellular populations while improving several markers of cartilage-producing activity.
These included increased expression of genes involved in cartilage formation, such as COL2A1, ACAN, and SOX9, along with increased production of type II collagen and proteoglycans.
Researchers also observed reductions in inflammatory signaling and increases in anabolic mediators associated with cartilage maintenance.
Importantly, dasatinib appeared to contribute directly to some of the cartilage-related anabolic effects, suggesting that its biological activity may extend beyond senescent-cell elimination.
Additional research published in The Spine Journal investigated D+Q in mice with lumbar facet joint osteoarthritis. Researchers observed reductions in chondrocyte senescence, improvements in cartilage-related biological activity, and attenuation of joint degeneration.
Together, these studies provide a scientific rationale for investigating senolytic treatment as a way to modify the biological environment of an osteoarthritic joint rather than focusing exclusively on its symptoms.
The Importance of Subchondral Bone and Aging Stem Cells
Cartilage is only one component of a healthy joint.
The subchondral bone immediately beneath the cartilage plays a critical role in distributing mechanical forces, supporting cartilage integrity, and maintaining normal joint function.
Emerging research suggests that cellular senescence within this underlying bone may contribute significantly to osteoarthritis progression.
A 2025 study published in Stem Cell Research & Therapy investigated the effects of senescent bone marrow mesenchymal stem cells on subchondral bone remodeling.
The researchers demonstrated that these dysfunctional cells could promote abnormal bone formation and sclerosis through senescence-associated inflammatory signaling.
In their animal model, D+Q treatment was associated with reduced senescent MSC populations, improved subchondral bone pathology, and less cartilage degeneration.
This is particularly interesting for regenerative medicine because it suggests that the condition of a patient's existing stem cell populations may influence the joint's overall biological health.
As we age, native regenerative cells may accumulate mitochondrial dysfunction, altered inflammatory signaling, and other characteristics associated with cellular aging.
Addressing these dysfunctional cell populations before introducing regenerative products may therefore represent a useful area of investigation.
Senolytic Therapy May Influence Joint Pain Independently of Cartilage Repair
Research published in Aging Cell in 2022 investigated senolytic interventions in aged mice with spontaneous osteoarthritis.
Investigators observed improvements in pain-related behavior associated with reduced peripheral nociceptive signaling.
Interestingly, these improvements occurred without corresponding structural restoration of the damaged joint.
This finding highlights an important distinction: joint pain and joint degeneration are related, but they are not identical biological processes.
An intervention may reduce inflammatory or nociceptive signaling without necessarily rebuilding cartilage.
The study suggests that senescence-associated pathways could potentially influence both the biological progression of joint disease and the mechanisms responsible for pain, although human clinical confirmation is needed.
Does Senolytic Therapy Actually Reduce Senescent Cells in Humans?
While laboratory and animal studies are encouraging, evidence of biological activity in humans is essential.
In a 2019 study published in EBioMedicine, researchers administered a short course of oral dasatinib and quercetin to nine patients with diabetic kidney disease.
Tissue biopsies obtained before and after treatment demonstrated reductions in several markers associated with cellular senescence, including approximately 35% fewer p16-positive cells, 17% fewer p21-positive cells, and 62% fewer SA-β-gal-positive cells in adipose tissue.
These findings provided early human evidence that D+Q treatment can reduce measurable senescence-associated cellular markers.
However, the study was small, lacked a placebo control group, and did not investigate joint disease.
A randomized clinical trial published in 2024 examined D+Q treatment in 60 postmenopausal women.
Although investigators did not observe a significant overall improvement in their primary bone-resorption endpoint, exploratory analyses suggested that women with higher baseline senescent-cell burden might experience more favorable biological responses.
This raises an intriguing possibility: the effectiveness of senolytic therapy may depend partly on the biological age and senescence burden of the individual rather than chronological age alone.
Why RegeneZone Uses Senolytic Preconditioning
At RegeneZone, our philosophy is that regenerative medicine should address the biological environment of the joint, not simply the damaged structure.
Our approach incorporates dasatinib and quercetin as a senolytic preconditioning strategy before selected regenerative joint injections.
The rationale is to address senescence-associated cellular dysfunction before introducing regenerative biologics, including extracellular matrix allografts and extracellular vesicle-based products.
The Dasatinib and Quercetin Dosing Protocol
One of the best-described human senolytic regimens comes from the 2019 study by Hickson and colleagues, published in EBioMedicine.
The investigators administered:
Dasatinib: 100 mg orally once daily
Quercetin: 500 mg orally twice daily (1,000 mg total daily)
Treatment duration: 3 consecutive days
The investigators subsequently evaluated changes in senescence-associated markers, reporting reductions in several cellular markers in adipose tissue.
This short, intermittent regimen is of particular research interest because it demonstrates that measurable biological changes can follow a brief course of treatment rather than requiring continuous administration.
However, this dosing schedule was investigated in patients with diabetic kidney disease, not in patients receiving regenerative joint injections. It is not a validated dosing protocol for osteoarthritis or joint preconditioning, and no evidence-based interval between D+Q administration and a regenerative injection has been established.
Dasatinib is an oncology medication with potentially serious risks, including myelosuppression, bleeding, infection, fluid retention, and drug interactions. Its use for senolysis is off-label and requires careful clinical evaluation and monitoring.
Preparing the Joint Before Regenerative Treatment
The scientific objective of senolytic preconditioning is to address several biological factors that may influence the response to regenerative treatment.
These include reducing senescence-associated cellular dysfunction, potentially decreasing SASP-related inflammatory signaling, improving the environment for cartilage maintenance, and addressing abnormal cellular activity in the subchondral bone.
Following preconditioning and appropriate clinical reassessment, the next stage of the RegeneZone approach involves the selected regenerative joint procedure.
The hypothesis is that improving the biological environment before treatment may support a more favorable response to subsequently administered regenerative products.
Although this strategy has a plausible scientific foundation, no controlled human study has established that D+Q pretreatment improves the effectiveness, safety, or durability of regenerative joint injections.
A New Philosophy: Prepare First, Regenerate Second
The future of regenerative medicine may depend as much on preparing the body for repair as it does on the regenerative products themselves.
Aging joints are not simply worn-out mechanical structures. They are living biological environments influenced by cellular senescence, inflammation, extracellular matrix degradation, and declining native regenerative cell function.
The growing research on dasatinib and quercetin offers a promising avenue for investigating these processes.
At RegeneZone, we are interested in moving beyond the conventional idea that regenerative medicine begins and ends with an injection.
Our approach considers what happens before the procedure, the condition of the tissues receiving treatment, and the biological factors that may influence the response.
Because regenerative medicine should not simply be about what we put into a joint. It should also be about the environment we prepare to receive it.
Selected Scientific References
Maurer et al. (2025). Senolytic Therapy Combining Dasatinib and Quercetin Restores the Chondrogenic Phenotype of Human Osteoarthritic Chondrocytes. Aging Cell.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11995296/
Zhao et al. (2025). Senolytics Cocktail Dasatinib and Quercetin Alleviate Chondrocyte Senescence and Facet Joint Osteoarthritis in Mice. The Spine Journal.
https://pubmed.ncbi.nlm.nih.gov/39343238/
Senescent Bone Marrow Mesenchymal Stem Cells Exacerbate Subchondral Bone Sclerosis and Osteoarthritis via the Senescence-Associated Secretory Phenotype. (2025). Stem Cell Research & Therapy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12751491/
Senolytic Drugs Relieve Pain by Reducing Peripheral Nociceptive Signaling Without Modifying Joint Tissue Damage in Spontaneous Osteoarthritis. (2022). Aging Cell.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9417227/
Hickson et al. (2019). Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib Plus Quercetin in Individuals with Diabetic Kidney Disease. EBioMedicine.
Farr et al. (2024). Targeting Cellular Senescence with Senolytics to Improve Skeletal Health in Older Humans.
Clinical note: Dasatinib and quercetin are not FDA-approved for senolytic treatment or osteoarthritis. Using D+Q before regenerative joint injections remains investigational, and clinical benefits from this treatment sequence have not been established.
